Cargando…
Probiotics modulate gastrointestinal microbiota after Helicobacter pylori eradication: A multicenter randomized double-blind placebo-controlled trial
BACKGROUND: Helicobacter pylori (H. pylori) eradication has been reported to cause short-term disruption of gut microbiota. It is acknowledged that probiotics supplementation mitigates side effects induced by H. pylori eradication, yet its role on alleviating dysbiosis of microbiota is obscure. OBJE...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9679295/ https://www.ncbi.nlm.nih.gov/pubmed/36426355 http://dx.doi.org/10.3389/fimmu.2022.1033063 |
_version_ | 1784834160643276800 |
---|---|
author | He, Cong Xie, Yong Zhu, Yin Zhuang, Kun Huo, Lijuan Yu, Yong Guo, Qiang Shu, Xu Xiong, Zhijuan Zhang, Zhenyu Lyu, Bin Lu, Nonghua |
author_facet | He, Cong Xie, Yong Zhu, Yin Zhuang, Kun Huo, Lijuan Yu, Yong Guo, Qiang Shu, Xu Xiong, Zhijuan Zhang, Zhenyu Lyu, Bin Lu, Nonghua |
author_sort | He, Cong |
collection | PubMed |
description | BACKGROUND: Helicobacter pylori (H. pylori) eradication has been reported to cause short-term disruption of gut microbiota. It is acknowledged that probiotics supplementation mitigates side effects induced by H. pylori eradication, yet its role on alleviating dysbiosis of microbiota is obscure. OBJECTIVES: To evaluate the impact of probiotics on gastrointestinal microbiota after eradication therapy. METHODS: This was a multicenter, double-blinded, randomized trial done at seven centers in China. A total of 276 treatment-naïve H. pylori-positive patients were randomly assigned to receive 14-day bismuth-containing quadruple therapy (esomeprazole, bismuth, amoxicillin, furazolidone) combined with probiotics (Bifidobacterium Tetragenous viable Bacteria Tablets) (n=140) or placebo (n=136) for 28 days. Saliva, gastric mucosa and fecal samples were collected before and after therapy for 16S rRNA gene sequencing. RESULTS: The incidence of gastrointestinal adverse events was lower in probiotics group compared to placebo group (23.6% vs 37.7%, p=0.016), while there was no significant difference in eradication rate. We found dramatic perturbations of gut microbiota immediately following eradication, with the predominance of Proteobacteria in replacement of commensal Firmicutes and Bacteroidetes, and gradually restored after two weeks. The reduction of gut Bacteroidetes caused by eradication drugs was neutralized with probiotics supplementation. The gastric microbiota was completely reconstituted with H. pylori depleted and other taxa flourished. Of note, patients treated with probiotics showed smaller fluctuations of gastric microbiota compared to those with placebo. We also observed changes of saliva microbiota after H. pylori eradication, illustrated by the overgrowth of Neisseria and depletion of Streptococcus. The expansion of some pathogenic genera, including Porphyromonas, Leptotrichia, in the mouth was suppressed by probiotics. CONCLUSION: This study not only demonstrated the beneficial effect of probiotics implementation on side events during H. pylori eradication but also provided a comprehensive profile of microbiome alterations along gastrointestinal tract that modulated by probiotics. |
format | Online Article Text |
id | pubmed-9679295 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96792952022-11-23 Probiotics modulate gastrointestinal microbiota after Helicobacter pylori eradication: A multicenter randomized double-blind placebo-controlled trial He, Cong Xie, Yong Zhu, Yin Zhuang, Kun Huo, Lijuan Yu, Yong Guo, Qiang Shu, Xu Xiong, Zhijuan Zhang, Zhenyu Lyu, Bin Lu, Nonghua Front Immunol Immunology BACKGROUND: Helicobacter pylori (H. pylori) eradication has been reported to cause short-term disruption of gut microbiota. It is acknowledged that probiotics supplementation mitigates side effects induced by H. pylori eradication, yet its role on alleviating dysbiosis of microbiota is obscure. OBJECTIVES: To evaluate the impact of probiotics on gastrointestinal microbiota after eradication therapy. METHODS: This was a multicenter, double-blinded, randomized trial done at seven centers in China. A total of 276 treatment-naïve H. pylori-positive patients were randomly assigned to receive 14-day bismuth-containing quadruple therapy (esomeprazole, bismuth, amoxicillin, furazolidone) combined with probiotics (Bifidobacterium Tetragenous viable Bacteria Tablets) (n=140) or placebo (n=136) for 28 days. Saliva, gastric mucosa and fecal samples were collected before and after therapy for 16S rRNA gene sequencing. RESULTS: The incidence of gastrointestinal adverse events was lower in probiotics group compared to placebo group (23.6% vs 37.7%, p=0.016), while there was no significant difference in eradication rate. We found dramatic perturbations of gut microbiota immediately following eradication, with the predominance of Proteobacteria in replacement of commensal Firmicutes and Bacteroidetes, and gradually restored after two weeks. The reduction of gut Bacteroidetes caused by eradication drugs was neutralized with probiotics supplementation. The gastric microbiota was completely reconstituted with H. pylori depleted and other taxa flourished. Of note, patients treated with probiotics showed smaller fluctuations of gastric microbiota compared to those with placebo. We also observed changes of saliva microbiota after H. pylori eradication, illustrated by the overgrowth of Neisseria and depletion of Streptococcus. The expansion of some pathogenic genera, including Porphyromonas, Leptotrichia, in the mouth was suppressed by probiotics. CONCLUSION: This study not only demonstrated the beneficial effect of probiotics implementation on side events during H. pylori eradication but also provided a comprehensive profile of microbiome alterations along gastrointestinal tract that modulated by probiotics. Frontiers Media S.A. 2022-11-08 /pmc/articles/PMC9679295/ /pubmed/36426355 http://dx.doi.org/10.3389/fimmu.2022.1033063 Text en Copyright © 2022 He, Xie, Zhu, Zhuang, Huo, Yu, Guo, Shu, Xiong, Zhang, Lyu and Lu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology He, Cong Xie, Yong Zhu, Yin Zhuang, Kun Huo, Lijuan Yu, Yong Guo, Qiang Shu, Xu Xiong, Zhijuan Zhang, Zhenyu Lyu, Bin Lu, Nonghua Probiotics modulate gastrointestinal microbiota after Helicobacter pylori eradication: A multicenter randomized double-blind placebo-controlled trial |
title | Probiotics modulate gastrointestinal microbiota after Helicobacter pylori eradication: A multicenter randomized double-blind placebo-controlled trial |
title_full | Probiotics modulate gastrointestinal microbiota after Helicobacter pylori eradication: A multicenter randomized double-blind placebo-controlled trial |
title_fullStr | Probiotics modulate gastrointestinal microbiota after Helicobacter pylori eradication: A multicenter randomized double-blind placebo-controlled trial |
title_full_unstemmed | Probiotics modulate gastrointestinal microbiota after Helicobacter pylori eradication: A multicenter randomized double-blind placebo-controlled trial |
title_short | Probiotics modulate gastrointestinal microbiota after Helicobacter pylori eradication: A multicenter randomized double-blind placebo-controlled trial |
title_sort | probiotics modulate gastrointestinal microbiota after helicobacter pylori eradication: a multicenter randomized double-blind placebo-controlled trial |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9679295/ https://www.ncbi.nlm.nih.gov/pubmed/36426355 http://dx.doi.org/10.3389/fimmu.2022.1033063 |
work_keys_str_mv | AT hecong probioticsmodulategastrointestinalmicrobiotaafterhelicobacterpylorieradicationamulticenterrandomizeddoubleblindplacebocontrolledtrial AT xieyong probioticsmodulategastrointestinalmicrobiotaafterhelicobacterpylorieradicationamulticenterrandomizeddoubleblindplacebocontrolledtrial AT zhuyin probioticsmodulategastrointestinalmicrobiotaafterhelicobacterpylorieradicationamulticenterrandomizeddoubleblindplacebocontrolledtrial AT zhuangkun probioticsmodulategastrointestinalmicrobiotaafterhelicobacterpylorieradicationamulticenterrandomizeddoubleblindplacebocontrolledtrial AT huolijuan probioticsmodulategastrointestinalmicrobiotaafterhelicobacterpylorieradicationamulticenterrandomizeddoubleblindplacebocontrolledtrial AT yuyong probioticsmodulategastrointestinalmicrobiotaafterhelicobacterpylorieradicationamulticenterrandomizeddoubleblindplacebocontrolledtrial AT guoqiang probioticsmodulategastrointestinalmicrobiotaafterhelicobacterpylorieradicationamulticenterrandomizeddoubleblindplacebocontrolledtrial AT shuxu probioticsmodulategastrointestinalmicrobiotaafterhelicobacterpylorieradicationamulticenterrandomizeddoubleblindplacebocontrolledtrial AT xiongzhijuan probioticsmodulategastrointestinalmicrobiotaafterhelicobacterpylorieradicationamulticenterrandomizeddoubleblindplacebocontrolledtrial AT zhangzhenyu probioticsmodulategastrointestinalmicrobiotaafterhelicobacterpylorieradicationamulticenterrandomizeddoubleblindplacebocontrolledtrial AT lyubin probioticsmodulategastrointestinalmicrobiotaafterhelicobacterpylorieradicationamulticenterrandomizeddoubleblindplacebocontrolledtrial AT lunonghua probioticsmodulategastrointestinalmicrobiotaafterhelicobacterpylorieradicationamulticenterrandomizeddoubleblindplacebocontrolledtrial |